Pharmaceutical - GlaxoSmithKline, Respiratory and Pulmonary

Filter

Popular Filters

1 to 25 of 68 results

Asthma drug market set to grow $23 billion by 2023

28-11-2014

The asthma treatment market value will grow across eight major countries (the USA, UK, France, Germany,…

AdvairAstraZenecaAustraliaEuropeGlaxoSmithKlineJapanMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySingulairSymbicortUSA

GlaxoSmithKline invests in Australia plant expansion

14-11-2014

UK pharma major GlaxoSmithKline’s Australian subsidiary today announced it will be investing A$31 million…

AustraliaFinancialGlaxoSmithKlinePharmaceuticalProductionRespiratory and PulmonaryVentolin HFA

IQWiG finds no added benefit for GSK’s Anoro Ellipta in COPD

21-10-2014

According to the findings of an early benefit assessment under the German Act on the Reform of the Market…

Anoro ElliptaGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationRespiratory and Pulmonary

Asthma’s treatment pipeline very strong as more personalized medicines emerge

Asthma’s treatment pipeline very strong as more personalized medicines emerge

26-09-2014

Asthma has a very strong drug pipeline, with almost 100 novel molecules or formulations currently in…

AstraZenecabenralizumabBosatriaCinquilGlaxoSmithKlineGlobalPharmaceuticalResearchRespiratory and PulmonaryTeva Pharmaceutical Industries

ERS 2014: GSK reports positive Phase III results of its mepolizumab in asthma

ERS 2014: GSK reports positive Phase III results of its mepolizumab in asthma

08-09-2014

UK pharma major GlaxoSmithKline has reported positive data from its Phase III asthma studies of mepolizumab,…

GlaxoSmithKlineGSKImmunosuppressantsmepolizumabMepolizumabPharmaceuticalResearchRespiratory and PulmonaryUK

US FDA backs approval of GSK’s Arnuity Ellipta for asthma

US FDA backs approval of GSK’s Arnuity Ellipta for asthma

21-08-2014

UK pharma giant GlaxoSmithKline revealed late yesterday that the US Food and Drug Administration has…

Arnuity ElliptaGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryUSA

Global asthma market to hit $18 billion by 2021 boosted by biologics

Global asthma market to hit $18 billion by 2021 boosted by biologics

14-08-2014

The market for asthma drugs is predicted to reach $18 billion by 2021, according to new research from…

AdvairAsthmaAstraZenecaBoehringer IngelheimBreoGlaxoSmithKlineGlobalMarkets & MarketingNatasha SpillerPharmaceuticalRespiratory and PulmonaryRespiratory therapySpirivaSymbicort

GSK and Theravance initiate global Phase III study for chronic obstructive pulmonary drug

GSK and Theravance initiate global Phase III study for chronic obstructive pulmonary drug

16-07-2014

UK pharma major GlaxoSmithKline and its US partner Theravance have started a global Phase III study,…

Breo ElliptaChronic obstructive pulmonary diseaseCOPDGlaxoSmithKlinePharmaceuticalRelvar ElliptaResearchRespiratory and PulmonaryRespiratory therapyTheravanceUKUSA

GSK’s Anoro Ellipta approved in Japan for COPD

GSK’s Anoro Ellipta approved in Japan for COPD

04-07-2014

UK pharma giant GlaxoSmithKline and US partner Theravance said this morning that the Japanese Ministry…

Anoro ElliptaGlaxoSmithKlineJapanPharmaceuticalRespiratory and PulmonaryTheravance

GSK and Theravance submit US sNDA for Breo Ellipta in asthma

GSK and Theravance submit US sNDA for Breo Ellipta in asthma

30-06-2014

US pharma giant GlaxoSmithKline and US partner Theravance have submitted a supplemental New Drug Application…

Breo ElliptaGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravanceUSA

EU5 payers looking to superior clinical efficacy for COPD

EU5 payers looking to superior clinical efficacy for COPD

30-06-2014

Surveyed pulmonologists in the European Union (EU5; France, Germany, Italy, Spain and the UK) estimate…

EuropeGlaxoSmithKlineMarkets & MarketingPharmaceuticalRelvarRespiratory and Pulmonary

Positive data on Incruse Ellipta added to Relvar/Breo Ellipta in COPD

Positive data on Incruse Ellipta added to Relvar/Breo Ellipta in COPD

11-06-2014

UK pharma giant GlaxoSmithKline and US partner Theravance have released positive results from two Phase…

Breo ElliptaGlaxoSmithKlineIncruse ElliptaPharmaceuticalRelvar ElliptaResearchRespiratory and PulmonaryTheravance

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

05-06-2014

UK pharma giant GlaxoSmithKline has agreed to a $105 million settlement with 44 US states and the District…

AdvairFinancialGlaxoSmithKlineLegalMarkets & MarketingNeurologicalPaxilPharmaceuticalRespiratory and PulmonaryUSAWellbutrin

GSK presents positive data for Incruse Ellipta added to Advair in COPD patients

GSK presents positive data for Incruse Ellipta added to Advair in COPD patients

20-05-2014

UK pharma major GlaxoSmithKline has released data showing the safety and efficacy of the addition of…

AdvairGlaxoSmithKlineHealth Medical PharmaHealth Medical PharmaIncruse ElliptaMedicinePharmaceuticalPulmonologyResearchRespiratory and PulmonaryRespiratory therapyUK

GlaxoSmithKline and Theravance’s Anoro Ellipta gains approval in EU

GlaxoSmithKline and Theravance’s Anoro Ellipta gains approval in EU

09-05-2014

The European Commission has granted marketing authorization for UK pharma giant GlaxoSmithKline and partner…

Anoro ElliptaEuropeGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravance

US FDA approves GSK’s Incruse Ellipta for COPD

US FDA approves GSK’s Incruse Ellipta for COPD

01-05-2014

The US Food and Drug Administration has approved UK pharma major GlaxoSmithKline’s Incruse (umeclidinium)…

Chronic lower respiratory diseasesCOPDGlaxoSmithKlineIncruseIncruse ElliptaMajorMedicinePharmaceuticalPulmonologyRegulationRespiratory and PulmonaryUKUSA

GSK gains EU marketing OK for Incruse for COPD; initiates tafenoquine Ph III program

GSK gains EU marketing OK for Incruse for COPD; initiates tafenoquine Ph III program

29-04-2014

UK pharma giant GlaxoSmithKline has received marketing authorization from the European Commission for…

EuropeGlaxoSmithKlineIncrusePharmaceuticalRespiratory and PulmonarytafenoquineTropical diseases

Canadian approval for GSK’s Incruse Ellipta as a treatment for COPD

17-04-2014

UK pharma giant GlaxoSmithKline says that Incruse Ellipta (umeclidinium) has received market authorization…

CanadaGlaxoSmithKlineIncruse ElliptaNorth AmericaPharmaceuticalRegulationRespiratory and Pulmonary

2014 “drugs to watch” as potential blockbusters

2014 “drugs to watch” as potential blockbusters

17-04-2014

The Thomson Reuters Intellectual Property & Science business has released its annual forecast of the…

AfrezzaAnoro ElliptaAnti-viralsCyramzaEli LillyGilead SciencesGlaxoSmithKlineidelalisibMannKindMarkets & MarketingOncologyPharmaceuticalRespiratory and PulmonarySovaldi

GSK faces bribery allegations in Poland

GSK faces bribery allegations in Poland

14-04-2014

UK pharma major GlaxoSmithKline is facing allegations of bribing doctors in Poland, according to the…

BBCGlaxoSmithKlineGSK regional managerLegalMajorMedicinePharmaceuticalPolandPulmonologyRespiratory and PulmonarySeretideUK

Positive results from Anoro Ellipta vs Seretide and Advair Diskus in patients in COPD

Positive results from Anoro Ellipta vs Seretide and Advair Diskus in patients in COPD

14-03-2014

GlaxoSmithKline and Theravance today announced positive results from three Phase III studies with their…

Advair DiskusAnoro ElliptaGlaxoSmithKlinePharmaceuticalResearchRespiratory and PulmonarySeretide

GSK’s mepolizumab succeeds in Ph III severe eosinophilic asthma trial

GSK’s mepolizumab succeeds in Ph III severe eosinophilic asthma trial

13-03-2014

UK pharma giant GlaxoSmithKline says that a pivotal Phase III study of mepolizumab, an investigational…

GlaxoSmithKlinemepolizumabPharmaceuticalResearchRespiratory and Pulmonary

GSK receives positive CHMP opinion for COPD drug Incruse

GSK receives positive CHMP opinion for COPD drug Incruse

21-02-2014

GlaxoSmithKline has announced that the European Medicines Agency’s Committee for Medicinal Products…

GlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryUKumeclidinium

1 to 25 of 68 results

Back to top